AXL Inhibitors: Status of Clinical Development

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The AXL signaling pathway is implicated in tumor progression and adverse patient outcomes in various cancers.
• AXL plays a critical role in cancer cell survival, metastasis, and the development of resistance to therapies.

Purpose of the Study:

• To review current strategies for targeting the AXL signaling pathway in the treatment of solid tumors and hematological malignancies.
• To highlight the therapeutic potential of AXL inhibitors in oncology.

Main Methods:

• Review of recent clinical development strategies for AXL-targeted therapies.
• Analysis of emerging data on AXL inhibitors, including tyrosine kinase inhibitors, monoclonal antibodies, antibody-drug conjugates, and soluble receptors.
• Examination of combination therapies involving AXL inhibitors and immune checkpoint inhibitors.

Main Results:

• AXL-targeted therapies are advancing through clinical development for various cancers.
• Combination of AXL inhibitors with immune checkpoint inhibitors shows early therapeutic promise.
• Further research is needed to identify predictive biomarkers and optimize treatment sequencing for AXL-targeted therapies.

Conclusions:

• AXL is a significant therapeutic target in oncology due to its role in tumor growth and drug resistance.
• Ongoing clinical trials will elucidate the efficacy of AXL inhibitors as monotherapy and in combination regimens.
• Targeting AXL represents a promising strategy for improving cancer treatment outcomes.